American Heart Journal
Volume 151, Issue 5 , Pages 985-991, May 2006

Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)–Added trial

  • John J.V. McMurray, MB, MD

      Affiliations

    • Department of Cardiology, Western Infirmary, Glasgow, Scotland
    • Corresponding Author InformationReprint requests: John J.V. McMurray, MB, MD, Department of Cardiology, Western Infirmary, G11 6NT Glasgow, UK.
    • ,
  • James B. Young, MD

      Affiliations

    • Medicine, Cleveland Clinic Foundation, Cleveland, OH
    • ,
  • Mark E. Dunlap, MD

      Affiliations

    • Case Western Reserve University and VA Medical Center, Cleveland, OH
    • ,
  • Christopher B. Granger, MD

      Affiliations

    • Duke University Medical Center, Durham, NC
    • ,
  • James Hainer, MD

      Affiliations

    • AstraZeneca LP, Wilmington, DE
    • ,
  • Eric L. Michelson, MD

      Affiliations

    • AstraZeneca LP, Wilmington, DE
    • ,
  • Steven Earle, PhD

      Affiliations

    • AstraZeneca LP, Wilmington, DE
    • ,
  • Bertil Olofsson, PhD

      Affiliations

    • AstraZeneca, R&D Mölndal, Sweden
    • ,
  • Jan Östergren, MD

      Affiliations

    • Department of Medicine, Karolinska University Hospital Solna, Stockholm, Sweden
    • ,
  • Salim Yusuf, MD, DPhil

      Affiliations

    • HGM-McMaster Clinic, Hamilton, Ontario, Canada
    • ,
  • Karl Swedberg, MD, PhD

      Affiliations

    • Department of Medicine, Sahlgrenska University Hospital/Östra, Göteborg, Sweden
    • ,
  • Marc A. Pfeffer, MD, PhD

      Affiliations

    • Brigham and Women's Hospital, Boston, MA
    • ,
  • on behalf of the CHARM Investigators

Received 30 December 2005; accepted 14 February 2006.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 The CHARM program was funded by AstraZeneca, Wilmington, DE, which was responsible for data collection and analysis. Academic leadership was provided by the executive committee who supervised the management of the study and was responsible for the interpretation of the data, preparation, review, and approval of the manuscript. Authors who are employees of AstraZeneca are identified as such. All other authors have received research grants, consultancy fees, and/or speaker fees from AstraZeneca.Guest editor of this manuscript is Harvey D. White, DSc.

PII: S0002-8703(06)00167-0

doi:10.1016/j.ahj.2006.02.028

American Heart Journal
Volume 151, Issue 5 , Pages 985-991, May 2006

Article Tools

* Image Usage & Resolution